Development and production of biopharmaceuticals are complex. Even minor impurities, orchanges in attributes such as glycosylation or charge heterogeneity, can have a profound impact on the safety and = ef cacy of the nal product. Traditionally, multiple analytical techniques have been required to assess the full range of biopharmaceutical product attributes. But the inevitable consequence of multiple analytical techniques is greater expenditures of time and resources.